SCHEMBL686903

SCHEMBL686903

CCCc1ccc([C@H](CC(=O)O)NC(=O)Nc2c(O)c(C)cn(Cc3ccccc3Cl)c2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.40
PTGER3 P43115 8/20 0.40
CNR2 P34972 1/20 0.38
ITGB1 P05556 7/20 0.36
ITGA4 P13612 7/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 1/20 0.35
CYP1A2 P05177 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688581 0.94 PTGER3 (0.44) SLC22A12PTGER3CNR2ITGB1ITGA4
SCHEMBL688053 0.92 PTGER3 (0.43) SLC22A12PTGER3CNR2KDM4EALDH1A1
SCHEMBL688284 0.91 PTGER3 (0.43) SLC22A12PTGER3CNR2ITGB1ITGA4
SCHEMBL686896 0.91 PTGER3 (0.44) SLC22A12PTGER3CNR2
SCHEMBL29371834 0.91 PTGER3 (0.44) SLC22A12PTGER3CNR2
SCHEMBL687923 0.90 PTGER3 (0.41) SLC22A12PTGER3CNR2ITGB1ITGA4
SCHEMBL686842 0.88 PTGER3 (0.45) SLC22A12PTGER3CNR2ITGB1ITGA4
SCHEMBL687127 0.88 PTGER3 (0.42) PTGER3CNR2MAPT
SCHEMBL686997 0.88 PTGER3 (0.39) SLC22A12PTGER3CNR2KDM4EALDH1A1
SCHEMBL688170 0.88 PTGER3 (0.41) SLC22A12PTGER3CNR2ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed